Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Frontier AI company Albert Invent today announced a strategic partnership with Kenvue Inc. (NYSE:KVUE), maker of consumer healt...
Johnson & Johnson stock trades near all-time highs with an upcoming Q3 earnings report acting as the next catalyst.
KFF poll shows falling trust in the CDC and HHS chief RFK Jr. as misinformation and partisan divides shape public views on vacc...
JP Morgan analyst Andrea Teixeira maintains Kenvue (NYSE:KVUE) with a Overweight and lowers the price target from $24 to $21.
U.S. stocks edged lower on Thursday, pausing after a record-setting run. The S&P 500 slipped 0.4% by midday in New York, re...
Citigroup analyst Filippo Falorni maintains Kenvue (NYSE:KVUE) with a Neutral and lowers the price target from $20 to $17.
B of A Securities analyst Anna Lizzul maintains Kenvue (NYSE:KVUE) with a Buy and lowers the price target from $25 to $21.
UBS analyst Peter Grom maintains Kenvue (NYSE:KVUE) with a Neutral and lowers the price target from $23 to $17.
Risk sentiment is taking a breather after days of a relentless rally, with all major Wall Street indexes trading in negative te...
